Harnessing the Therapeutic Potential of Peptides for Synergistic Treatment of Alzheimer’s Disease by Targeting Aβ Aggregation, Metal-Mediated Aβ Aggregation, Cholinesterase, Tau Degradation, and Oxidative Stress

• Published in: ACS chemical neuroscience 2024-07, Vol.15 (14), p.2545-2564
• Main Authors: Singh, Kamaljot, Kaur, Anupamjeet, Goyal, Bhupesh, Goyal, Deepti
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Amyloid beta-Peptides - metabolism; Animals; Cholinesterases - metabolism; Humans; Oxidative Stress - drug effects; Peptides - pharmacology; Peptides - therapeutic use; Protein Aggregates - drug effects; Protein Aggregates - physiology; Protein Aggregation, Pathological - drug therapy; Protein Aggregation, Pathological - metabolism; tau Proteins - metabolism
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.4c00246

Alzheimer’s disease (AD) is a progressive multifaceted neurodegenerative disease and remains a formidable global health challenge. The current medication for AD gives symptomatic relief and, thus, urges us to look for alternative disease-modifying therapies based on a multitarget directed approach. Looking at the remarkable progress made in peptide drug development in the last decade and the benefits associated with peptides, they offer valuable chemotypes [multitarget directed ligands (MTDLs)] as AD therapeutics. This review recapitulates the current developments made in harnessing peptides as MTDLs in combating AD by targeting multiple key pathways involved in the disease’s progression. The peptides hold immense potential and represent a convincing avenue in the pursuit of novel AD therapeutics. While hurdles remain, ongoing research offers hope that peptides may eventually provide a multifaceted approach to combat AD.